Literature DB >> 18203658

The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting.

Stephen Barclay1, Stanislas Pol, David Mutimer, Yves Benhamou, Peter R Mills, Peter C Hayes, Sheila Cameron, William Carman, William Cameron.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18203658     DOI： 10.1016/j.jcv.2007.11.017

Source DB:  PubMed          Journal:  J Clin Virol        ISSN： 1386-6532            Impact factor:   3.168


× No keyword cloud information.
  8 in total

Review 1.  Occult hepatitis B: clinical implications and treatment decisions.

Authors:  Paul Schmeltzer; Kenneth E Sherman
Journal:  Dig Dis Sci       Date:  2010-10-07       Impact factor: 3.199

Review 2.  Antiviral treatment for chronic hepatitis B in renal transplant patients.

Authors:  Ezequiel Ridruejo
Journal:  World J Hepatol       Date:  2015-02-27

3.  Patients with hematological malignancies and serological signs of prior resolved hepatitis B.

Authors:  Massimo Marignani; Elia Gigante; Paola Begini; Alfredo Marzano; Michela di Fonzo; Ilaria Deli; Sara Gallina; Maria Christina Cox; Gianfranco Delle Fave
Journal:  World J Gastrointest Oncol       Date:  2012-03-15

Review 4.  Occult hepatitis B virus infection.

Authors:  Min-Sun Kwak; Yoon Jun Kim
Journal:  World J Hepatol       Date:  2014-12-27

5.  Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.

Authors:  Akihiro Tamori; Tatsuya Koike; Hitoshi Goto; Shigeyuki Wakitani; Masahiro Tada; Hiroyasu Morikawa; Masaru Enomoto; Masaaki Inaba; Tatsuya Nakatani; Masayuki Hino; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2011-01-19       Impact factor: 7.527

6.  Controversies about occult hepatitis B virus infection.

Authors:  Ersan Ozaslan; Tugrul Purnak
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

7.  Low rates of hepatitis B virus screening at the onset of chemotherapy.

Authors:  Jessica P Hwang; Michael J Fisch; Hong Zhang; Michael A Kallen; Mark J Routbort; Lincy S Lal; John M Vierling; Maria E Suarez-Almazor
Journal:  J Oncol Pract       Date:  2012-06-12       Impact factor: 3.840

Review 8.  Occult HBV infection in the oncohematological setting.

Authors:  C Sagnelli; M Macera; M Pisaturo; R Zampino; M Coppola; E Sagnelli
Journal:  Infection       Date:  2016-04-13       Impact factor: 3.553
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.